StockNews.AI
DXR
StockNews.AI
173 days

Daxor Corporation Expands Blood Volume Analysis Technology to Major New Jersey Hospitals

1. Daxor expands blood volume analysis in New Jersey's top academic health system. 2. Implementation of BVA analyzers improves patient care outcomes in critical situations. 3. Company anticipates accelerated sales growth throughout 2025 due to market momentum. 4. Daxor’s technology uniquely quantifies blood volume via FDA-cleared testing. 5. CEO touts sales strategy effectiveness and expanding market footprint.

6m saved
Insight
Article

FAQ

Why Bullish?

Adoption by a leading health system signals increased demand for Daxor’s technology. Historically, partnerships with major medical institutions have led to increased stock valuations.

How important is it?

The article outlines significant partnerships and sales growth prospects, crucial for DXR’s market position.

Why Long Term?

Ongoing adoption and alignment with market trends suggest prolonged benefits. Positive health outcomes will likely lead to wider acceptance and market saturation.

Related Companies

MDGSABBVCNCHCAUNH
Leading Academic Health System Adopts Daxor’s Innovative Blood Volume Measurement Capabilities at Two Key Facilities Oak Ridge, TN, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the expansion of its blood volume analysis (BVA) at two major hospitals within New Jersey’s largest academic health care system. Based on current market momentum and expanding pipeline of opportunities, the Company expects to maintain this accelerated sales trajectory throughout 2025. These two prestigious hospitals are in the process of implementing on-site BVA analyzers, enabling immediate access to precise blood volume measurements for critical care decisions. This investment allows their clinical teams to optimize fluid management, reduce hospital stays, and improve outcomes for heart failure and critical care patients. "The continued expansion of our market footprint demonstrates the effectiveness of our growth strategy. The resources we have dedicated to strengthening our sales and marketing capabilities are delivering meaningful results," said Michael Feldschuh, CEO and President of Daxor. "This adoption by a leading healthcare system reflects the growing acknowledgment that our blood volume analysis technology plays a vital role in enhancing patient care outcomes." About Daxor Corporation Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE. Forward-Looking Statements Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Relations Contact:Bret ShapiroSr. Managing Partner, CORE IR1-516-222-2560brets@coreir.com

Related News